Healthcare >> CEO Interviews >> October 14, 2002
STUART PELTZ, is President and Chief Executive Officer of PTC
Therapeutics Inc. Dr. Peltz is a leader in the investigation of mRNA
turnover and translation and has been involved in developing the first
biochemical assays to investigate the regulation of mRNA turnover as
well as in demonstrating the strong connection between the processes of
translation and mRNA turnover. Dr. Peltz is widely published and serves
on National Institutes of Health and American Cancer Society committees.
Dr. Peltz is a recognized scientific leader in the area of post-
transcriptional control processes and his work was instrumental in
identifying and characterizing components of the nonsense-mediated mRNA
decay pathway. His laboratory has established the notion that factors
that are involved in nonsense-mediated mRNA turnover are also involved
in modulating the processes of translation termination and programmed -1
ribosomal frameshifting. Dr. Peltz received his PhD at the McArdle
Laboratory for Cancer Research at the University of Wisconsin. Profile
and then bring us up to the present time?
Dr. Peltz: PTC stands for Post Transcriptional Control. It was founded
out of
